Softwr

Research · head to head

Genedata vs Suzy

Genedata logo

Genedata

Research

Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher

From
On request
Rated
-
Full reviewWebsite
Suzy logo

Suzy

Research

Enterprise consumer insights on an owned US panel, resold elsewhere through Cint

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Suzy the proprietary Crowdtap panel is US only at around a million consumers with roughly 50,000 verified active monthly, and everything international is resold Cint supply, so the speed and verification argument that justifies the price applies to one market.
  • They diverge on capability: Genedata covers Screener, Suzy covers Suzy Insights.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Genedata and Suzy actually diverge.

Attributes where Genedata and Suzy differ
AttributeGenedataSuzy
PlatformsWeb, On-premise, Private cloudWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Genedata

  • Screener
  • Biologics
  • Bioprocess
  • Expressionist
  • Selector
  • Profiler
  • Instrument integration
  • GxP-capable deployments

Only in Suzy

  • Suzy Insights
  • Suzy Live
  • Suzy Audiences
  • Suzy Speaks
  • Video open ends
  • Advanced methods
  • Data Explorer
  • AI Decision Engine

What people use each for

The jobs each tool is most often brought in to do.

Genedata

  • A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Suzy
  • A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Suzy
  • A process development group standardising bioprocess run data across sites for modelling and scale-upnot Suzy
  • A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Suzy

Suzy

  • A US consumer packaged goods brand that needs concept testing back the same day because a packaging decision is due at the end of the week.not Genedata
  • An insights department running an always-on brand tracker on a US audience without re-commissioning fieldwork every wave.not Genedata
  • A team that wants quant screening followed immediately by moderated qual with the same respondents, rather than two vendors and two timelines.not Genedata
  • A product team testing claims and price sensitivity with MaxDiff and conjoint on a panel they can go back to repeatedly.not Genedata

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Genedata

  • There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
  • Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
  • Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
  • Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
  • Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.

Suzy

  • The proprietary Crowdtap panel is US only at around a million consumers with roughly 50,000 verified active monthly, and everything international is resold Cint supply, so the speed and verification argument that justifies the price applies to one market.
  • Customers have asked Suzy to build proprietary panels with native speakers in Germany, France, Japan, India and Brazil, which confirms those do not exist today; multi-market brands need a second vendor and lose the single-source comparison.
  • Reviewers report the panel skews female and millennial and falls short on Gen Z, male and various ethnic segments, and that niche or B2B audiences are hard to reach, so quota fills can be slow or impossible.
  • Reviewers also raise data trust concerns about respondent sourcing and vetting, including one naming bot responses and acquiescence bias, which is the standing risk of any single owned opt-in panel with repeat respondents.
  • Pricing is a sales-led annual commitment reported to run around $88,000 a year at the median with onboarding fees and per-seat charges on top, with no trial, no self-serve and no pay-per-response option, so there is no cheap way to validate fit.
  • Credits are pre-committed monthly against forecast activity with no published overage rate, so under-use is wasted spend and a busy quarter triggers an unbudgeted purchase.
  • Integrations are genuinely thin: there is no public integrations page and no public API documentation, and the only confirmed external data relationship is Cint, so expect to move data by export.

Pricing, plan by plan

Genedata

On request
  • Genedata platform licence$undefined/year
    • Each platform, such as Screener or Biologics, licensed separately
    • Annual enterprise subscription scoped on users, sites and data volume
    • Implementation and scientific configuration services quoted as a separate programme

Suzy

On request
  • Suzy$undefined/year
    • Annual subscription with pre-committed monthly research credits
    • Credit volume set against forecast study activity
    • Onboarding fees and per-seat charges quoted separately

Which should you pick?

Choose Genedata if

  • You need screener.
  • You work on Web, On-premise, Private cloud.
  • You also want biologics.
Genedata review

Choose Suzy if

  • You need suzy insights.
  • You work on Web, iOS, Android.
  • You also want suzy live.
Suzy review

Questions people ask

Is Genedata or Suzy better?
Neither clearly leads. Genedata starts at On request and Suzy at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Genedata or Suzy?
Genedata starts at On request and Suzy at On request.
Does Genedata or Suzy run on more platforms?
Genedata runs on Web, On-premise, Private cloud. Suzy runs on Web, iOS, Android.
What is Genedata best used for?
Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Suzy is typically brought in for.
What can Genedata do that Suzy cannot?
Genedata covers Screener, Biologics, Bioprocess, Expressionist. Suzy covers Suzy Insights, Suzy Live, Suzy Audiences, Suzy Speaks.

Answered from the vendors’ own pages

Genedata: Who owns Genedata?

Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.

Suzy: Is the panel global?

No. Crowdtap, the owned panel, is US only. International studies run on Cint supply, which you could contract for directly.

Genedata: Is there a small-team or starter option?

No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.

Suzy: What does it cost?

Nothing is published. Third-party analysis puts the median contract around $88,000 a year with a range roughly $34,000 to $187,500, plus onboarding and per-seat fees.

Genedata: Do I buy one product or the whole suite?

Each platform is licensed separately. Most customers license two or three and integrate between them.

Suzy: Is there an API?

Nothing public. Suzy publishes no API documentation and no named connectors beyond Cint. Verify any integration requirement in the sales call before committing.

Genedata: Can it be used in a GxP environment?

Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.

Suzy: What changed in April 2026?

Suzy repositioned as an AI Decision Engine with Intelligence and Impact modules, while headcount fell from about 230 to 186. Ask how the roadmap is now split between that and the classic survey and qual products.

Share

Related pages

More on Genedata

More on Suzy

Keep looking

Other head to heads